title: The effect of topical bevacizumab as an adjunctive therapy for corneal neovascularization.
authors.forename: Leyla
authors.initials: L
authors.lastname: Asena
authors.forename: Yonca A
authors.initials: YA
authors.lastname: Akova
authors.forename: Altug
authors.initials: A
authors.lastname: Cetinkaya
authors.forename: Cem
authors.initials: C
authors.lastname: Kucukerdonmez
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D016510:Corneal Neovascularization / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab